NEW YORK, Nov. 19, 2024 /PRNewswire/ — Lindus Health, the “anti-CRO” running radically faster, more reliable clinical trials for life science pioneers, has introduced their versatile contract research organization (CRO), site, and technology offering tailor-made to the execution of infectious disease trials.

Clinical development of infectious disease treatments and diagnostics must account for complexities such as diverse and evolving pathogens, seasonality and localization of study sites, and enrollment at the appropriate time during infection. Having enrolled over 5,000 patients in infectious disease studies across the US, EU, and UK, Lindus Health is well-equipped to handle the unique challenges within this therapeutic area.

Lindus Health’s latest solution for the infectious disease market segment leverages their full-spectrum CRO and site services, rooted in deep expertise in running infectious disease clinical trials. They are able to recruit diverse study populations at twice the speed of traditional CROs through their expansive recruitment capabilities, including targeted digital outreach campaigns, healthcare and community organization collaborations, and electronic health record (EHR) screening from a repository of over 30 million patients.

“Infectious disease studies require swift and adaptable approaches for execution and recruitment to keep pace with evolving pathogens and public health needs,” said Meri Beckwith, co-founder of Lindus Health. “Therefore speed of execution and access to real-time data are essential, while ensuring enrollment of diverse and representative patient populations.”

The “All-in-One Infectious Disease CRO” offers a comprehensive suite of resources and services to support infectious disease research, including:

Full-service CRO solutions: From protocol writing and study startup to close-out and data delivery, Lindus Health’s clinical operations team oversees all aspects of infectious disease trials, handling all project management and administrative responsibilities.Innovative recruitment strategies: With partnerships across primary care, urgent care, and local community groups as well as EHR screening and direct-to-patient marketing, Lindus employs advanced methods to quickly recruit diverse patient populations in infectious disease studies.Adaptable eClinical software: Citrus™, Lindus’ proprietary clinical research platform custom-built for each trial, stitches together essential tools such as clinical trial management software (CTMS), electronic data capture (EDC), telehealth, and eConsent, providing a true all-in-one solution for cohesive study management.Regulatory and industry insights: Lindus offers expertise on regulatory standards and emerging developments within infectious disease research.Comprehensive site services: Lindus’ site operations team collaborates closely with principal investigators and research staff to execute women’s health trials across single-site, multi-site, hybrid, and fully virtual environments.

“The escalating prevalence and rapid evolution of infectious pathogens present significant challenges to developing interventions to treat, detect, and protect against infectious diseases,” said Dr. Robert Langer, Institute Professor at Massachusetts Institute of Technology and Scientific Advisor to Lindus Health. “With their innovative, agile approaches to trial execution, I believe Lindus Health is well-equipped to quickly adapt and overcome these challenges as they arise.”

Lindus Health is devoted to supporting infectious disease sponsors in bringing groundbreaking treatments and diagnostics to patients and healthcare providers by streamlining all stages of the clinical trial workstream.

To learn more about the “All-in-One Infectious Disease CRO” offering, click here.

About Lindus Health

Lindus Health is an anti-CRO running radically faster and more reliable trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. This is achieved  through a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), a world-class clinical operations team with its unique software platform, and access to over 30 million Electronic Health Records.

Clinical trials are the biggest bottleneck to advances in healthcare. Lindus Health removes this constraint by handling the end-to-end execution of clinical studies, including design, patient recruitment, clinical data capture, monitoring and project management.

To date, Lindus Health has delivered clinical trials across the US, UK and Europe to tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $24M from investors including Peter Thiel, CREANDUM, Firstminute Capital, Seedcamp, Hambro Perks, Amino Collective and Calm/Storm.

Lindus Health Media Contact:
Jodi Perkins
Amendola for Lindus Health
jperkins@acmarketingpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lindus-health-rolls-out-all-in-one-infectious-disease-cro-bespoke-to-clinical-trials-for-infectious-disease-interventions-302309386.html

SOURCE Lindus Health

Investing in the future by improving ergonomics in Rosenheim, Germany facility

AUBURN, Mass., Nov. 19, 2024 /PRNewswire-PRWeb/ — PI, the market and technology leader for high-precision motion control, positioning technology, and piezo applications, has completed the construction of additional electronics production space at its Rosenheim, Germany site.

With investments of around $2.3M and a 30% increase in space, PI is strengthening its global development and production center and the economic development of the region. For 2025, another investment of $2M has been approved.

The expansion will enable production capacities of precision motion control and nanopositioning technology products to be further increased in order to meet the demands of customers from the semiconductor, photonics, laser processing, and life sciences industries.

See a variety of photonics, laser technology, and nanopositioning applications covered by PI system technologies »here.

Industries Served
Photonics, Semiconductors, Laser Technology, Microscopy, Life Sciences

PI Americas
https://www.pi-usa.us | info@pi-usa.us | (508) 832-3456

Applications Blog | Videos | X | LinkedIn

Media Contact

Ceramics Manufacturing Production Expansion, PI (Physik Instrumnente) LP, (508) 832-3456, press-release@pi-usa.us, www.pi-usa.us

Twitter

View original content to download multimedia:https://www.prweb.com/releases/pis-new-expansion-for-higher-electronics-manufacturing-capacities-and-shorter-lead-times-302308759.html

SOURCE PI (Physik Instrumnente) LP; PI (Physik Instrumnente) LP

Reflects Company’s Focus on Disciplined Capital Deployment

INDIANAPOLIS, Nov. 19, 2024 /PRNewswire/ — Corteva, Inc. (NYSE: CTVA) today announced that its Board of Directors authorized a new $3 billion share repurchase program. The authorization is immediately effective, does not expire, and gives management discretion in determining the conditions under which shares may be purchased.

This newly authorized program is in addition to the Company’s existing $2.0 billion program announced in September 2022, which had approximately $750 million remaining as of September 30, 2024. Shares of the Company’s common stock may be repurchased periodically in open-market or private transactions. The actual timing, number and value of shares repurchased under the Company’s authorized share repurchase program will depend on a variety of factors including the market price of Corteva common stock, general market and economic conditions, applicable legal requirements and other business considerations and uses of capital, including organic growth, dividends, and acquisitions.

“This action underscores our Board’s confidence in Corteva’s future and our commitment to returning capital to shareholders,” said Chuck Magro, Chief Executive Officer, Corteva Agriscience. “Corteva’s new share repurchase program, together with the Company’s dividend increase earlier this year, demonstrate Corteva’s strong financial outlook and commitment to a disciplined capital deployment strategy.”

For updates on the Company’s strategy, technology pipeline, and financial framework, join Corteva’s previously announced Investor Day, today at 9 a.m. Eastern Time. Registration is available on the Events and Presentations Page of the Corteva Investor Relations website. A replay will be available on the website following the webcast. 

About Corteva
Corteva, Inc. (NYSE: CTVA) is a global pure-play agriculture company that combines industry-leading innovation, high-touch customer engagement and operational execution to profitably deliver solutions for the world’s most pressing agriculture challenges. Corteva generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. With some of the most recognized brands in agriculture and a technology pipeline well positioned to drive growth, the company is committed to maximizing productivity for farmers, while working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. More information can be found at www.corteva.com.

Cautionary Statement About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like “plans,” “expects,” “will,” “anticipates,” “believes,” “intends,” “projects,” “estimates” or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva’s capital allocation plans, performance outlook, and strategy are forward-looking statements. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement or other estimate, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements or other estimates is included in the “Risk Factors” section of Corteva’s Annual Report on Form 10-K, as modified by subsequent reports on Form 10-Q and Current Reports on Form 8-K.

View original content to download multimedia:https://www.prnewswire.com/news-releases/corteva-agriscience-announces-3-billion-share-repurchase-program-302309807.html

SOURCE Corteva Agriscience